Sarcoma trials in France

In France 72 Also abroad 605

72 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Analysis of Circulating Tumor Markers in Blood
Where
Montpellier
Age
18 years and over
People
992
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT04025541
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Avignon, Bron, Caen Cedex 5, Clermont Ferrand Cedex 1, Lyon, Montpellier Cedex 5, Quimper Cedex, Reims Cedex, Saint-Herblain, Strasbourg Cedex, Suresnes, Villejuif
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
No phaseNot yet taking people in France
Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas
Where
Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Poitiers, Rennes, Rouen, Saint-Denis, Saint-Etienne, Strasbourg, Toulouse, Tours, Vandœuvre-lès-Nancy, Villejuif
Age
Up to 25 years
People
150
Run by
Institut Curie
See details and how to joinNCT07924384
Phase 1Taking people
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Where
Bordeaux, Lille, Lyon, Nice
Age
18 years and over
People
65 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT06641908 · EU 2024-513687-26-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bordeaux, Brest, Lille, Montpellier, Pierre-Bénite, Villejuif
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Bordeaux, Lyon, Marseille, Nantes, Villejuif
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 1Taking people
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Where
Marseille, Villejuif
Age
24 months to 18 years
People
20 worldwide
Run by
ITM Solucin GmbH
See details and how to joinNCT06441331 · EU 2024-512831-66-00
Phase 3Taking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Avignon, Boulogne-Billancourt, Clermont Ferrand Cedex1, Dijon, Nice, Nimes Cedex 9, Quimper Cedex, Valenciennes
Age
18 years and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
Phase 3Taking people
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
Where
Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Dijon, Grenoble, La Réunion, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Poitiers, Reims, Rennes, Rouen, Saint-Etienne, Saint-Herblain, Strasbourg, Toulouse, Tours, Vandœuvre-lès-Nancy, Villejuif
Age
4 years and over
People
530 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07871864
Phase 3Taking people
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
Where
Besancon Cedex, Caen Cedex 5, Clermont-Ferrand, Dijon, Limoges, Lyon, Marseille, Montpellier Cedex 5, Nice Cedex 2, Paris, Poitiers, Reims, Rennes Cedex, Rouen, Saint-Herblain Cedex, Strasbourg, Strasbourg Cedex 2, Toulouse, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
600
Run by
Institut Claudius Regaud
See details and how to joinNCT04307277 · EU 2024-515384-62-00
Phase 1Taking people
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Where
Vandœuvre-lès-Nancy
Age
18 years and over
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07261631
No phaseTaking people
CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.
Where
Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Paris, Toulouse, Villejuif
Age
18 years and over
People
205
Run by
Institut Bergonié
See details and how to joinNCT02789384
No phaseTaking people
Sarcoma Care Adherence and Survival in Strasbourg
Where
Strasbourg
Age
18 years and over
People
900
Run by
University Hospital, Strasbourg, France
See details and how to joinNCT07864870
Phase 3Taking people
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Where
Lyon, Montpellier, Paris, Strasbourg, Villejuif
Age
18 years and over
People
250 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04031677
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Where
Bordeaux, Lyon, Villejuif
People
64 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07602777
Phase 1/2Not yet taking people in France
Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
Where
Bordeaux, Lille, Lyon, Marseille, Nancy, Paris, Strasbourg, Toulouse
Age
6 years to 40 years
People
89
Run by
University Hospital, Strasbourg, France
See details and how to joinNCT07853105
Phase 3Taking people
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Where
Clichy
Age
18 years and over
People
16 worldwide
Run by
Rezolute
See details and how to joinNCT06881992
Phase 1/2Taking people
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Where
Angers, Bordeaux, Lyon, Marseille, Villejuif
Age
Up to 25 years
People
75 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT04094610 · EU 2023-506464-14-00
No phaseTaking people
Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer
Where
Bordeaux
Age
15 years to 49 years
People
70
Run by
Institut Bergonié
See details and how to joinNCT07614620
No phaseNot yet taking people in France
Benefits of Early Collaboration Between Oncologists and Palliative Care Physicians in Cases of Unplanned Hospitalization for Patients With Metastatic Cancer
Where
Lille
Age
18 years and over
People
493
Run by
Centre Oscar Lambret
See details and how to joinNCT07490106
Phase 1Taking people
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Lyon, Marseille, Toulouse, Vandoeuvre Les Nancy Cedex
Age
18 years and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00
Phase 2Not yet taking people in France
Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma
Where
Villejuif
Age
18 years and over
People
80
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07802652
Phase 1/2Taking people
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Where
Lyon, Villejuif
Age
18 years and over
People
270 worldwide
Run by
Adcendo ApS
See details and how to joinNCT06797999 · EU 2024-516900-41-00
Phase 4Not yet taking people in France
Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG
Where
Bron, Caluire-et-Cuire, Chevilly-Larue, Dijon, Lille Cedex, Lyon Cedex 04, Marseille, Paris, PARIS, Paris Cedex 20, Pierre-Bénite, Rennes Cedex, Saint-Cloud, Strasbourg Cedex 2, Toulouse, Villejuif
Age
65 years and over
People
794
Run by
Institut Gustave Roussy
See details and how to join2025-523610-83-00 · EU 2025-523610-83-00
Phase 1Taking people
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Where
Lyon, Villejuif
Age
12 years to 85 years
People
411 worldwide
Run by
Inhibrx Biosciences, Inc
See details and how to joinNCT03715933 · EU 2023-508139-29-00